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Abstract
Background: Bardet-Biedl syndrome (BBS) is a rare genetic disorder that features retinal degeneration, obesity,
polydactyly, learning disabilities and renal abnormalities. The diagnosis is often missed at birth, the median age
at diagnosis being 9 years. In the attempt to shed light on BBS and improve its diagnosis and treatment, we
evaluated the genotype-phenotype relationship in patients with a molecular diagnosis of BBS.
Methods: We analyzed three common BBS genes, BBS1, BBS10 and BBS2, in 25 Italian patients fulfilling the clinical
criteria of BBS. In 12 patients, we identified gene-specific biallelic variants and thus correlated genotype to the
ophthalmic, renal and audio-vestibular phenotypes.
Results: At least one sequence variant was found in 60% of patients. The most common mutated gene was BBS1
followed by BBS10. Of the 17 sequence variants we found, 11 have not previously been associated with BBS. In
12 patients, we identified biallelic pathogenic variants; they had retinitis pigmentosa with early onset of visual
impairment. However, retinal dystrophy was less severe in patients with BBS1 than in those with BBS10 variants.
Overall, we found a high prevalence of renal dysmorphism and dysfunction. Notably, patients with BBS10 variants
had the most severe renal impairment, which resulted in a critical decline in renal function. All the patients who
underwent audio-vestibular evaluation had dysfunction of the cochlear outer hair cells, thus confirming the
presence of hearing defects.
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Conclusion: BBS1, BBS2 and BBS10 are major causative genes in Italian BBS patients. BBS10 was associated with the
worse outcome in terms of the renal, ocular and audiovestibular phenotypes. Cochlear dysfunction should be
included among the hallmarks of BBS.
Keywords: Bardet-Biedl syndrome, BBS1, BBS2 and BBS10 gene variants, Ciliopathy, Renal, ocular and audiovestibular
phenotype
Background
Bardet-Biedl syndrome (BBS) is a systemic hereditary
disorder characterized by the coexistence of rod-cone
dystrophy, polydactyly, obesity, cognitive impairment,
and renal dysfunction. Its prevalence varies among geo-
graphic areas, ranging from 1:160,000 in North Europe
to 1:13,500 in Kuwait and Newfoundland [1]. The
phenotype is heterogeneous and the diagnosis is often
missed at birth. Polydactyly or syndactyly are generally
the first signs recognized at birth, while visual defects,
obesity and cognitive impairment develop during the
first year of age [2].
Retinal degeneration occurs in over 90% of BBS pa-
tients and visual prognosis is poor [3]. Retinal dystrophy
in BBS is progressive and varies in severity. Patients
experience progressive night blindness, followed by
photophobia and loss of central and color vision. At
clinical level, they show marked reduction of electro-
retinogram (ERG) amplitude, which depends on a pri-
mary loss of rod photoreceptors followed by cone death
[4]. An in vivo micro-structural analysis of retinal layers
in patients with BBS revealed macular involvement [5].
The prevalence of renal impairment varies among stud-
ies, which however ultimately indicated that few BBS
patients have a reduced glomerular filtration rate (GFR),
while most have an abnormal renal structure and a
normal GFR [2, 6]. Whether an abnormal kidney struc-
ture predisposes to progressive renal failure remains to
be elucidated. Interestingly, hearing loss is not consid-
ered a main feature of BBS, and has been reported in
only two studies [7, 8].
BBS is considered an autosomal recessive disease char-
acterized by genetic heterogeneity, which at least partly
explains the clinical variability of this condition, al-
though oligogenic inheritance has also been hypothe-
sized [1, 9, 10]. Indeed, biallelic mutations have been
reported in 19 genes, namely BBS1, BBS2, ARL6, BBS4,
BBS5, BBS6 (MKKS), BBS7, BBS8 (TTC8), BBS9, BBS10,
BBS11 (TRIM32), BBS12, MKS1, CEP290, C2ORF86,
SDCCAG8, LZTFL1, BBIP1, IFT27, which account for
70–80% of BBS cases [11, 12]. The various BBS-
associated genes encode proteins involved in the regula-
tion of ciliary structure, biogenesis and function [1].
Therefore, cilia dysfunction is the main hypothesis of
BBS pathogenesis [1]. In this context, it is notable that
BBS shares several characteristic features with such
other ciliopathies as Meckel, Joubert, and Senior-Locken
syndromes.
Here, we report the genetic and clinical findings (ocular,
renal and audio-vestibular phenotypes) in a cohort of
Italian patients who fulfilled the diagnostic criteria of BBS.
We focused the molecular analysis on the most common
disease-associated genes in Caucasians, namely, BBS1,
BBS10 and BBS2 [13]. Our study aims to expand the
spectrum of pathogenic variants associated to BBS in Italy
and, by analyzing genotype-phenotype correlations, to
improve the diagnosis and treatment of this complex
genetic disorder.
Methods
Patients
Twenty-five patients referring to the Eye Clinic of the
Second University of Naples (Italy) met the clinical diag-
nostic criteria for BBS according to Beales et al. [7]. The
female/male ratio was 2:3 and mean age was 25.6 years
(range: 9–65 years). All procedures were conducted ac-
cording to international guidelines and to the tenets of
the Helsinki Declaration 2008 and 2013. Each patient
(or parent or legal guardian) gave written consent to
undergo DNA analysis, which was performed according
to the guidelines for genetic testing approved by the
Ministero della Salute, Rome, Italy (G.U. n. 224, 23th
September 2004).
Molecular study
Genomic DNA was extracted from peripheral blood
leukocytes with the automated MagNA Pure LC system
(Roche Diagnostics, Milan, Italy). DNA samples were first
analyzed with the BBS–ALMS1 mutation array (Asper
Biotech, Tartu, Estonia) that detects 253 sequence variants
in the BBS1-7, BBS9, BBS10, BBS12 and ALMS1 genes.
All exons and flanking intronic sequences of the BBS1,
BBS2 and BBS10 genes were amplified with M13-tailed
primer pairs and fully sequenced with M13 primers by
using the Big Dye™ Terminator v.3.1 Sequencing kit and
the ABI Prism 3730 DNA Analyzer (Applied Biosystems-
Life Technologies Italia, Monza, Italy). Mutation number-
ing is based on the genomic and transcript reference
sequences of BBS1 (NG_009093.1, NM_024649.4), BBS2
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(NG_009312.1, NM_031885.3) and BBS10 (NG_016357.1,
NM_024685.3).
To predict the impact of the novel sequence variants
on the expression of BBS1, BBS2 and BBS10, we used
the online tools Variant Effect Predictor (VEP) [14] and
MutationTaster [15] that predict the effect of known and
new variants (single nucleotide polymorphisms [SNPs],
insertions, deletions, copy number variations or struc-
tural variants) on genes, transcripts, and protein se-
quences, as well as on regulatory regions. In the case of
missense changes, VEP also assigns scale-invariant fea-
ture transform (SIFT) and polymorphism phenotyping
v2 (PolyPhen-2) probability scores of the pathogenetic
effect on the putative protein variant. VEP and Muta-
tionTaster not only handle single amino acid substitu-
tions, but also insertions and deletions; they also identify
non-canonical splice sites.
Ophthalmological study
All 25 patients underwent a complete ophthalmological
examination including best-corrected visual acuity (BCVA)
measured using the Snellen chart, slit-lamp anterior seg-
ment examination, fundus examination, fundus photog-
raphy, Goldmann visual field examination, standard ERG
and optical coherence tomography (OCT). The ERG was
recorded with a Ganzfield stimulator following the guide-
lines of the International Society of Clinical Electrophysi-
ology of Vision [16]. OCT was performed with new
generation tomography, which uses spectral domain-based
techniques that allow the acquisition scans or 5 linear or a
retinal area of 6 × 6 mm2 through 512 (horizontal) × 128
(vertical) scans (SD-OCT, Cirrus HD OCT, Carl Zeiss,
Dublin, CA, USA).
Renal study
Renal function was evaluated in 21 patients. Glomerular
function was evaluated by estimating the GFR and the
urine albumin-to-creatinine ratio (ACR). Albumin was
measured in the early morning urine sample with a
standard immunochemical method and expressed as
urine ACR (mg/g). GFR was estimated according to the
Modification of Diet In Renal Disease study group and
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) [17], using standardized plasma creatinine
measurement. In children, GFR was estimated with the
Schwartz formula: GFR [(mL/min/1.73 m 2) = k × height
(cm)/serum creatinine (mg/dL)]. The normal estimated
GFR (eGFR) is 80–120 mL/min/1.73 m2; eGFR < 90 mL/
min/1.73 m2 indicates impaired renal function and
eGFR < 60 mL/min/1.73 m2 represents an increased risk
factor for an adverse renal outcome. Moreover, to track
longitudinal changes in GFR, we assessed eGFR 3 years
after the first visit in patients with biallelic mutation of
BBS1 and BBS10. Tubular function was analyzed in
patients with eGFR > 60 ml/min/1.73 m2. Acid-base bal-
ance was evaluated on arterial blood; urinary and plasma
electrolytes were also measured. Renal concentrating
ability was assessed by measuring urine osmolality 12 h
after water restriction (Osmometer model 3320, A. De
Mari, Italy). Urine osmolality < 750 mOsm/kg indicates a
defect in urine concentrating capability. Renal morph-
ology was determined by ultrasound.
Audio-vestibular study
Six genotyped patients (5 men and 1 woman) aged
between 13 and 38 years underwent audio-vestibular
function testing. Information about drug history, pre-
peri- and post-partum problems, previous audiological
disorders, head trauma or neurological defects (e.g., his-
tory of migraine, epilepsy, vertigo) was obtained for all
patients.
The hearing threshold was evaluated by liminal pure
tone audiometry and assessment of perception by verbal
speech audiometry. Subjects with a hearing threshold >
20 dB hearing level on the middle and/or high frequen-
cies were considered to have hearing loss. The imped-
ance analysis to evaluate the middle ear functioning was
performed according to the guidelines of the American
Speech-Language-Hearing Association. The presence of
inner ear damage was verified by means of distortion
product otoacustic emission (DPOAE). DPOAE was
measured with a Madsen Cappella instrument, which
generates two primary frequency tones, 2f1 and 2f2, with
a stimulus frequency separation of f1/f2. Intensity of the
custom stimulus was 40 dB sound pressure level (SPL)
at both frequencies. The DPOAE was recorded by auto-
matic scanning of the 250–8000 Hz frequency interval
focused on the pure tone audiometric test frequencies.
Auditory evoked potentials were evaluated with standard
parameters. Three chloride silver electrodes were located
in the vertex (active), mastoid (right or left) and fore-
head (ground) positions. Electrode impedances were
maintained at ≤ 7 kΩ. Stimuli for auditory brainstem re-
sponse recording were digitized at a rate of 20 kHz, and
presented over headphones. Stimuli were 100 μs clicks
presented monaurally at 110 dB SPL. Broadband noise
at 70 dB SPL was presented to the opposite ear to mask
any stimulation via acoustic cross talk. Clicks were pre-
sented at a rate of 21/s in 4-min runs. A conventional
method of alternating click stimulus polarity was used to
reduce stimulus artifacts in the average waveforms.
Band-pass filtered the signals between 30 and 3000 Hz.
The average waveform was focused on a period extend-
ing from 10 ms before the stimulus to 10 ms after the
stimulus. Vestibular function was evaluated with statoki-
netic tests (Romberg, sensitized Romberg), detection of
spontaneous nystagmus with video nystagmography, de-
tection of evoked nystagmus with the head shaking test
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(HST) and the bithermal caloric test. The latter was per-
formed with the Fitzgerald Hallpike method [18]. The
ears were stimulated by irrigation with hot water (44 °C)
and cold (30 °C) water. Patients were placed in a supine
position with head flexed forward 30°, so that the
straight line that joins the tragus to the outer canthus of
eye was vertical. Irrigation was carried out with 250 ml
of water at a flow rate about 5–8 ml/s for 40 s. The nys-
tagmic reaction was induced in a few seconds and
reached the maximum about 60 s after stimulation.
Results
We enrolled 25 patients from 24 unrelated families. In
addition to retinitis pigmentosa (RP), the main features
of our patients that were consistent with the clinical
diagnosis of BBS were postaxial polydactyly (21/25 pa-
tients), obesity (15/25 patients), a history of obesity (2/
25 patients), renal abnormalities (18/21 patients). We
found that 8/15 males had a history of hypogonadism,
four of whom had cryptorchidism; 4/10 females had
congenital abnormalities of the urogenital tract. More-
over, 18/25 patients showed intellectual disabilities in-
cluding delay in learning development during early
childhood and the need for educational support teachers.
Consanguinity or presumed consanguinity (geographic
isolates) was reported in 24% of patients (6/25).
All 25 patients underwent molecular analysis. First, we
applied the BBS–ALMS1 mutation array, which revealed
known sequence variants in 6/25 patients. These muta-
tions affected the BBS1, BBS2 and BBS10 genes; there-
fore, we sequenced these genes in patients with one or
no array-detected mutation. Sequencing confirmed the
array data and revealed 12 additional sequence changes.
Overall, our analysis revealed at least one sequence vari-
ant in 15/25 patients (60%). We found that 12/25
patients (about 48%) had biallelic putative disease-
causing variants, which supported the clinical diagnosis.
Table 1 illustrates the molecular data. Seven unrelated
patients have sequence variants in BBS1; 5 of them have
biallelic variants. Of the 8 independent BBS1 variant
alleles, 4 have sequence changes not previously linked to
BBS. In summary, among the 10 independent BBS1
alleles that we sequenced in the patients with BBS1 vari-
ants, 30% carry known sequence variants, 50% carry
sequence changes not previously linked to BBS, and 20%
are normal (Fig. 1). The patient who carries the monoal-
lelic p.V568M missense change in BBS1 also has new
biallelic pathogenic variants in BBS2. Overall, 5 patients
Table 1 Sequence variants identified in the BBS patients who tested positive to the molecular analysis
Patient ID Genotype
BBS1 BBS2 BBS10
P.1a c.664G>C/c.664G>C (p.G222R) N/N N/N
P.2a c.664G>C/c.664G>C (p.G222R) na na
P.3a,b c.1169T>G/c.1169T>G (p.M390R) na na
P.4a,b c.1169T>G / c.1169T>G (p.M390R) na na
P.5a c.1169T>G / c.1169T>G (p.M390R) na na
P.6 c.1169T>G/c.1642delC
(p.M390R/p.L548Wfs*31)
na na
P.7 c.592-59G>A/N N/N N/N
P.8 c.1702G>A/N (p.V568M) c.84delC/c.1059dupT
(p.P29Rfs*50/p.N354X)
N/N
P.9 N/N c.225T>G/c.225T>G (p.V75G) N/N
P.10 N/N c.2144G>A/N (p.R715Q) N/N
P.11 N/N c.986T>C/N (p. M329T) N/N
P.12 N/N c.535-79_90del/N c.2137_2140del/c.962A>G
(p.K713Ffs*16/p.Y321C)
P.13 na na c.235dupA/c.271dupT
(T79Nfs*17/p.C91LfsX5)
P.14a na na c.509T>C/c.509T>C (p.L170S)
P.15a N/N N/N c.641T>A/c.641T>A (p.V214E)
In bold, variants not previously linked to the BBS phenotype. For cDNA numbering, +1 corresponds to the A of the ATG translation initiation codon, which is
codon 1. Reference gene sequences were BBS1 (NG_009093.1, NM_024649.4), BBS2 (NG_009312.1, NM_031885.3), BBS10 (NG_016357.1, NM_024685.3)
N gene-specific normal allele, n.a. not analyzed
aWith consanguineous parents
bPatients 3 and 4 are siblings
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carry BBS2 sequence variants, but only 2 have a BBS2
genotype (biallelic variants) that is consistent with the
syndrome. In fact, two other patients have BBS2 mono-
alleic variants, i.e., the new c.2144G > A (p.R715Q) and
the c.986 T > C (p.M329T) (rs201146063) SNP, respect-
ively, and no mutation in BBS1 or BBS10. Another pa-
tient has a new monoallelic intronic sequence variant in
BBS2 (c.535-79_90del) and also biallelic, likely patho-
genic variants in BBS10. In summary, among the 10 in-
dependent BBS2 alleles that we sequenced, 30% carry
known sequence variants, 40% carry sequence changes not
previously linked to BBS, and 30% are normal (Fig. 1).
Overall, 4 patients have biallelic pathogenic variants in
BBS10 (about 16%). We found that 4/6 (67%, Fig. 1) inde-
pendent BBS10 alleles carry new sequence variants, i.e.,
c.641 T >A (p.V214E), c.235dupA (p.T79Nfs*17), c.962A >
G (p.Y321C) and c.2137_2140del (p.K713Ffs11*724Iext*1).
Except for one case (Table 1, P.9), our homozygous BBS pa-
tients have consanguineous parents. In all cases, Mendelian
segregation of the variant alleles was confirmed in parents
and, when available, in unaffected siblings.
Bioinformatic prediction indicated that all the new se-
quence variants in the coding regions of BBS1, BBS2
and BBS10 were very likely “disease-causing”, whereas
the two intronic variants were possible polymorphisms
(Additional file 1: Table S1). Notably, many of the
variants we identified are listed in the SNP database
(National Center for Biotechnology Information, NCBI),
all with a minor allele frequency < 0.0001 (Additional
file 1: Table S1); however, this is the first report that
links them to the BBS phenotype.
Genotype to ocular phenotype correlation
All patients with biallelic mutations (12/12) had visual
defects (Table 2). Nine of these patients were affected by
legal blindness having a visual acuity less than or equal
to 20/200 (0.1 decimals); 3/12 patients had a visual acu-
ity between 20/100 (0.2 decimals) and 20/70 (about 0.3
decimals). All 12 patients were able to perceive light.
Visual impairment was not congenital, however 66.6% of
patients had horizontal nystagmus, 58.3% strabismus
and 50.0% had cataracts. At fundus examination, nine
patients had osteoblast-like pigment clusters, mainly
located on the equator, narrowing of retinal blood ves-
sels, and optic disc pallor, which indicate diffuse retinal
pigment epithelial dystrophy (Fig. 2a); three of them had
macular dystrophy. In the remaining three patients, we
observed widespread tapetoretinal degeneration and the
absence of retinal pigment epithelium (Fig. 2b). All the
12 genotyped patients underwent ERG; they showed an
extinguished, not age-related scotopic and photopic
electroretinogram. Despite the nystagmus and fixation
instability and low visual acuity, OCT images were
acquired in nine patients, and these showed reduced
macular thickness and retinal pigment epithelium dys-
trophy. Four patients showed an epiretinal membrane
and three patients had signs of vitreomacular traction
syndrome (Fig. 2c). One patient had a macular lamellar
hole (Fig. 2d).
Genotype-phenotype correlation revealed that the six
patients with biallelic mutations in BBS1 (aged 9 to
70 years) had a BCVA ranging from light perception to
0.3 decimals; four of them had a BCVA equal to or bet-
ter than 1/10, three patients had nystagmus and five
exotropia. Typical RP associated with subcapsular cata-
ract was present in four patients, all over 25 years of
age. The six BBS1-mutated patients presented extin-
guished scotopic and photopic ERG responses. OCT
examination was performed only in four patients, three
of whom showed vitreoretinal abnormalities (Table 2).
The two patients with biallelic mutations in BBS2 had
a BCVA ≤ 0.02 decimal and nystagmus; one of them also
Fig. 1 Prevalence of known vs the novel BBS1, BBS2, BBS10 alleles in our genotyped BBS patients. Bars indicate, for the three groups of patients
(BBS1, BBS2, BBS10), the percentage of independent alleles with new (dark grey), known (intermediate grey), normal alleles (light grey)
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developed exotropia in the second decade of life. Both
patients had diffuse retinal pigment epithelium dys-
trophy without cataract, and the oldest developed
vitreoretinal abnormalities at OCT at the age of 19 years.
In both cases, the scotopic and photopic ERG responses
were extinguished.
We found that three of the four patients with biallelic
variants in BBS10 showed a BCVA of light perception;
the remaining one had nystagmus associated with
exotropia. All four showed typical RP; in the two eldest
subjects (31 and 40 years old, respectively), subcapsular
cataract also appeared at 30 years of age. Scotopic and
photopic ERG responses were extinguished in all cases;
OCT examination revealed vitreoretinal abnormalities in
the three subjects we analyzed (Table 2). Despite the
relatively small number of patients with a known geno-
type, genotype-phenotype correlation analysis revealed
that, although BCVA reduction was age-related, BBS1-
mutated patients had a significantly better visual acuity
(p ≤ 0.006), with a slower progression of BCVA reduc-
tion (0.03 decimals/year; p < 0.01), compared with our
BBS10- and BBS2-mutated patients.
Genotype to renal phenotype correlation
We evaluated the renal phenotype in 9/12 BBS patients
with a positive molecular test (Table 2). We obtained by
telephone interview information about the renal function-
ality of the three patients who did not undergo renal
examination. Interestingly, a 70-year-old woman, who was
homozygote for the common BBS1 mutation p.M390R
(patient P.4, Table 2), underwent radical nephrectomy for
a suspicious renal mass, 20 years earlier. Figure 3a corre-
lates the patients’ eGFR with genotype. A young BBS10
patient with congenital multicystic renal dysplasia, who
was diagnosed with end-stage renal disease at the age of
23 years, had the lowest eGFR, and the eGFR reduc-
tion was associated to albuminuria and hypertension.
The eGFR exceeded 90 ml/min/1.73 m2 in the other
two BBS10 patients, which however manifested tubu-
lar dysfunctions. In the patients with biallelic muta-
tions in BBS1 or BBS2, eGFR exceeded 90 ml/min/
1.73 m2.
We also evaluated changes in eGFR in BBS1 and
BBS10 patients (Fig. 3b) three years after baseline. The
rate of decline (ΔGFR) correlated with GFR at baseline.
In fact, renal dysfunction progressed faster in the patient
with the lowest GFR. Interestingly, all patients with
BBS10 mutations had ΔGFR higher than 10%, whereas it
was lower than 10% in the BBS1-mutated patients. The
ACR, a marker of glomerular damage, exceeded 30 mg/g
only in two patients, both with biallelic mutations in
BBS10 (Fig. 3c), whereas it was lower than 30 mg/g in
our BBS1 and BBS2 patients.
Tubular function was evaluated only in subjects with
an eGFR >60 ml/min/1.73 m2 (8/9 genotyped patients).
The most common tubular dysfunction we found was a
Fig. 2 Representative images of the ocular findings in the BBS patients analyzed. Fundus photography showing a narrowing of retinal blood
vessels, diffuse retinal pigment epithelial dystrophy with pigment clusters in mid-periphery; b narrowing of retinal blood vessels, widespread
tapetoretinal degeneration and absence of pigment clusters. OCT scan showing c vitreomacular traction syndrome with retinal pigment
epithelium dystrophy; (d) a macular lamellar hole with retinal pigment epithelium dystrophy
Esposito et al. BMC Medical Genetics  (2017) 18:10 Page 7 of 12
defect in urine concentrating ability, in agreement with a
previous report [17]. All the three patients with biallelic
mutations in BBS10 had hyposthenuria even 12 h after
water restriction (Fig. 3d) and therefore they were af-
fected by renal dysfunction. In contrast, urine concen-
trating ability was normal in 3/4 patients with mutated
BBS1 and in both the BBS2-mutated patients (Fig. 3d).
Plasma electrolytes were within normal range in all
patients (Additional file 1: Table S2). The mean concen-
trations of Na+ and K+ were normal, and Na+ and Cl−
fractional excretions (FE%) were lower than 1% in all
patients except one with the BBS10 mutation, who
showed a slight increase in the fractional excretion of so-
dium, FENa+, and of chlorine, FECl−, (1.04 and 1.41%,
respectively). Acid-base status was normal in all patients,
except in one BBS1 patient who was affected by meta-
bolic acidosis. The urine Ca+2/creatinine (UCa/Cr) ratio
was <0.2 mg/mg in all patients except one.
Abnormal kidney ultrasound appearance is a common
feature of BBS patients [17]. Accordingly, in our cohort,
8/9 genotyped patients showed a broad range of kidney
anatomical variations, i.e., parenchymal and peri-pelvic
cysts, renal hypoplasia, pelvic dilation and fetal lobula-
tions (Additional file 1: Table S3). We noted that the
severity of structural abnormalities correlated with the
severity of renal dysfunction.
Genotype to audiovestibular phenotype correlation
Tonal audiometry analysis revealed cochlear sensori-
neural hearing loss (SNHL) in 3/6 patients (Additional
file 1: Table S4); one had moderate bilateral SNHL, one
mild bilateral SNHL, and one mild SNHL in the right
ear. Another patient had a mixed moderate hearing loss
more pronounced in the right ear. Hearing impairment
in two patients required a hearing aid. Impedentiometry
showed a type “A” normal tympanogram and normal
stapedial reflexes in five patients (Table 2). However, at
the Metz recruitment test, patient P.9 who had moderate
SNHL had a considerably reduced dynamic range, i.e.
the gap between the acoustic reflex threshold and the
pure-tone audiometry hearing threshold level, which
indicates cochlear pathology. The patient with mixed
hearing loss showed a type “B” tympanogram and absent
reflexes. All six patients had no otoacustic emission
(Additional file 1: Table S5).
In the six patients we tested, speech audiometry head-
phones were normal; two patients had difficulty in verbal
comprehension. No patient experienced true rotatory ver-
tigo or dizziness during the vestibular test. Spontaneous
nystagmus occurred in one patient. Positional nystagmus
was observed in three patients (50%). In one patient, HST
was positive and the caloric test showed a pathological
caloric weakness in the right ear. The morphology and
Fig. 3 Analysis of renal function. a eGFR, calculated according to the CKD-EPI formula, in our BBS patients. The most severe renal dysfunction
occurred in a patient carrying biallelic BBS10 mutations. b Relative eGFR decline in 3 years. eGFR was estimated at baseline (T0) and after 3 years
(TIII). Relative eGFR change (ΔGFR) during 3 years is expressed as percentage (%) of the T0. c Urine albumin-to-creatinine ratio (ACR). Two of three
mutated patients showed ACR above 30 mg/g; the other patient showed normal ACR. d Maximal urine concentrating ability. Urine osmolality
was measured in the second morning urine void, after overnight fasting and water restriction
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latency of the auditory brain response waves were normal
in four patients. The latency of the I, III and V waves was
increased in one patient, and only the V wave was ob-
served at 80 dB hearing level in another patient.
Discussion
Bardet-Biedl syndrome, a rare clinically and genetic-
ally heterogeneous disorder, is often misdiagnosed due
to the high phenotypic variability and mainly because
it shares several characteristic features with other
ciliopathies [1]. Here we describe genetic and some
clinical features of 12 BBS Italian patients and report
the genotype-phenotype correlation.
Twenty-five Italian patients fulfilling the clinical cri-
teria of BBS underwent molecular analysis of the BBS1,
BBS10 and BBS2 genes because pathogenic variants in
these genes have been found in 23%, 20% and 8% of BBS
patients, respectively worldwide [13, 19]. We identified
21 independent alleles. Twelve families had biallelic ge-
notypes that were consistent with the disease phenotype.
Overall, we identified 17 different sequence variants, 6
known and 11 not previously linked to the disease, in
about 60% of our patients, which indicates BBS1, BBS2
and BBS10 are frequently mutated in Italian patients.
We also found monoallelic variants in BBS1 and BBS2
in two patients with biallelic pathogenic variants in
BBS2 and BBS10, respectively, which suggests the possi-
bility of triallelism. We were unable to verify triallelic in-
heritance because these patients are the only affected
members of their families. BBS1 is the most frequently
mutated gene in our cohort (28% of patients). Notably,
two unrelated patients are homozygous for the p.G222R
substitution in BBS1, which therefore represents 20% of
BBS1-variant alleles in our cohort. The minor allele
frequency reported in the ExAC database (Additional
file 1: Table S1) indicates this variant is very rare world-
wide. Therefore, p.G222R might be a founder disease
allele, in Italy. Also p.M390R was frequent in our cohort
of patients (30% of our BBS1 variant alleles). Notably, the
Exome Variant Server database records p.M390R in
0.25% (G = 23/T = 8567) of BBS1 alleles of individuals
of European-African descent. It has also been re-
ported in approximately 80% of Caucasian BBS1-posi-
tive patients [19, 20]. Therefore, we cannot consider
p.M390R a founder allele in Italy.
Surprisingly, we identified seven independent variant
alleles in BBS2 and only six in BBS10. However,
whereas all the BBS10-mutated patients have genotypes
fully consistent with the disease, only 2/5 BBS2-mu-
tated patients have unambiguous pathogenic genotypes;
the remaining three patients are heterozygous carriers
of variants with a predicted low pathogenic significance
(Additional file 1: Table S1).
Twelve of the variants we identified were not in the
Human Gene Mutation Database (Version 2015.4) or in
the Exome Variant Server. Five are point/subtle deletions
or duplications that lead to a frameshift and/or premature
stop codon, and therefore can be reasonably considered
pathogenic. A further five are nucleotide substitutions that
cause missense changes, and, in all cases, bioinformatic
tools predicted that they exert potential pathogenic effects.
Although these five substitutions are listed in the SNP
database, they have not previously been found in BBS pa-
tients. The remaining two intronic sequence variants are
predicted to be possible polymorphisms. In this context,
segregation of the new variant alleles we found in the
“biallelic” families strongly supports their pathogenic role.
In the two patients with potential triallelism [21], the
clinical picture of the patient with biallelic mutations in
BBS2 and one putative pathogenic missense change in
BBS1 was particularly serious; in fact, this patient was
born with a severe congenital aortic stenosis. This find-
ing, which is unusual in BBS, negatively affected progno-
sis and caused the patient’s death at the age of 18 years.
Since we limited our genetic analysis to three genes, we
cannot exclude that other genotyped patients may have
mutations in other genes that could exert an epistatic
effect. In particular, two adult siblings (P.3 and P.4 in
Tables 1 and 2) homozygous for the common BBS1 vari-
ant p.M390R have different BBS phenotypes. This find-
ing could be consistent with triallelism, also based on
reports that some homozygotes for the p.M390R variant
may or may not manifest the disease [20, 21]. However,
it is noteworthy that the elder of our two siblings was
the most severely affected and that BBS has an age-
dependent penetrance and variable expressivity [22].
Ophthalmologic analysis revealed that visual acuity
was age-related in the 12 genotyped patients. In fact, the
visual defect was more severe in patients over 19 years
of age (visual acuity ≤ 20/200) than in children (visual
acuity between 20/100 and 20/70). No patient lost the
ability to perceive light. Genotype-phenotype correlation
indicated a severe reduction in BCVA in all patients ex-
cept the two BBS1-mutated children probably because
of their young age. Also the appearance of fundus abnor-
malities correlated with age. In fact, pigment-type osteo-
blasts, narrowing of the retinal vessels and pallor of the
optic disc occurred late in the disease, namely, at a mean
age 35.8 years in 8/12 (75%) patients. Instead, a “salt and
pepper” fundus, which is considered a harbinger of ret-
inal disease, appeared at a mean age of 15 years in 4/12
(25%) patients. In most cases, macular changes started
in the early teens, whereas bone spicule pigments oc-
curred mainly in early adulthood.
The scotopic and photopic components of ERG were
altered in all the 12 genotyped patients. Eight of these
patients (75%) underwent OCT study, which confirmed
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that the most frequent findings were outer retina thinning
in the macular region and dystrophy of the pigmented epi-
thelium [5]. Unlike a previous report [23], loss of “lamin-
ation” of the retina was not gene-related in our cohort. The
retinal structure abnormalities in our patients did not cor-
relate with genotype, age or disease severity.
We previously reported that the prevalence of vitreoret-
inal abnormalities in BBS is twice that in RP patients [24].
The most frequent abnormalities in RP patients were
cystoid macular edema (20%) followed by epiretinal mem-
brane (16%); vitreo-macular traction was reported in only
5% of patients [24]. Forty-four per cent of our BBS patients
show an epiretinal membrane and 33.3% vitreo-macular
traction, while no patient had cystoid macular edema.
Renal dysfunction was frequent in our cohort. The
four BBS1-mutated patients we analyzed had mild renal
abnormalities, normal eGFR and a normal electrolyte
balance. One patient was affected by chronic metabolic
acidosis. The ultrasound appearance of the kidney was
unremarkable in one patient, while the others showed
fetal lobulation or isolated parenchymal cysts. Kidney size
and cortical thickness were normal in all patients of this
BBS1 subgroup. Only one BBS1 patient had hyposthe-
nuria. Modifier genes may have contributed to the onset
of this dysfunction, which however is the most frequent
renal dysfunction in BBS.
The two BBS2-mutated patients had a normal eGFR
and tubular function, and a mild renal phenotype, similar
to the BBS1-mutated patients. However, the ultrasound
renal appearance differed greatly between the two groups
of patients. The former had typical pelvic dilation/peripel-
vic cysts, whereas the latter had only mild fetal lobulation.
The three BBS10-mutated patients we analyzed have
renal dysfunction. The most severely affected patient has
two frameshift mutations, both leading to a non-
functional protein. He was born with a renal malformation
and was diagnosed with end stage renal disease at the age
of 23 years. The other two BBS10-mutated adults have
normal eGFR. However, one has a high ACR, which is a
marker of glomerular damage. Both these BBS10-mutated
patients had defective urine concentrating ability and a
normal eGFR. We recently reported that BBS10 knock-
down affected forskolin-dependent AQP2 trafficking to
the apical membrane of epithelial tubular cells, thus pro-
viding a potential explanation for hyposthenuria [25]. In
addition, our finding that the decline of eGFR in three
years was more severe in BBS10-mutated patients than in
BBS1-mutated patients indicates that BBS10 deficiency is
related to a poor renal prognosis [26]. Therefore, we con-
clude that, in our cohort of patients, BBS10 variant alleles
are associated to severe kidney dysfunction.
The audiological study revealed that two BBS10-mu-
tated patients and one BBS2-mutated patient had cochlear
SNHL. In contrast, our BBS1-mutated patients have no or
a mixed hearing impairment. These results differ from
previous reports that hearing loss, mainly due to conduct-
ive loss, is a minor sign of BBS [8]. Two of our patients,
affected by sensorineural and mixed hearing loss, respect-
ively, were successfully treated with hearing aids. There-
fore, patients with suspected BBS should undergo hearing
evaluation. In addition, our DPOAE results shed light on
the BBS phenotype. In fact, because all our BBS patients
had abnormal DPOAEs, we concluded that they had alter-
ation of outer hair cell function. This agrees with evidence
that the BBS phenotype arises from a ciliary dysfunction
and consequently it would affect tissues in which hair cells
are present. Therefore, DPOAEs may be useful for the
early detection of cochlear damage in BBS patients.
Vestibular function analysis suggested abnormalities in
the nystagmographic framework in 4/6 patients (67%),
which could be explained by the sharp decline in visual
acuity. In one case, we hypothesized the presence of a
unilateral peripheral vestibular lesion. Notably, two
young patients have the same BBS1 genotype (homozy-
gous p.G222R), but very different hearing phenotypes
even though they are of about the same age. Also in this
case, the variable expressivity of BBS could reflect an
epistatic effect of a putative triallelism.
Conclusion
In our cohort of Italian BBS patients there is a high preva-
lence of RP with early onset of visual impairment, a high
prevalence of renal dysmorphism and dysfunction, and of
subclinical hearing defects that, although generally poorly
substantiated, are a useful hallmark of BBS. BBS1, BBS2
and BBS10 are major causative genes also in Italian BBS
patients and the identification of new mutations demon-
strates a high allelic heterogeneity. Pathogenic variants of
BBS10 correlated with a worse outcome, at least in terms
of renal, ocular and audiovestibular phenotypes. As BBS10
variants severely affect renal structure and function, pa-
tients manifesting kidney malformation should be scanned
for mutations of this gene. Overall, our study may help to
improve the identification of this complex disorder.
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